A New Dawn in Cardio & Vascular Protection

Friday 4th & Saturday 5th May 2007

A New Dawn in Cardio & Vascular Protection

Madrid, Spain

Cardio- and cerebrovascular disease are a major cause of death and disability worldwide; around 7.1 million deaths, as well as two-thirds of strokes and one-half of ischaemic heart disease, are attributable to non-optimal blood pressure control. Powerful and sustained blood pressure reduction using renin-angiotensin system (RAS) blockade may be of importance in the prevention of stroke in patients with metabolic risk factors and in the prevention of renal disease progression in patients with type 2 diabetes. Identifying patients at high risk of cardiovascular disease is of pivotal importance, and a number of tools have been generated to estimate a patient's total cardiovascular risk. Once identified, therapy to reduce the modifiable risk factors, including lifestyle changes and pharmacotherapy, can be initiated as appropriate. However, it is clear that novel treatment approaches are required for these patients, and one approach that holds great potential is dual RAS blockade with angiotensin II receptor blockers (ARBs) and angiotensin-converting enzyme (ACE) inhibitors. RAS blockade has been shown to have a beneficial effect on the endothelial and vascular dysfunction that can lead to target organ damage and to both cardiovascular and renal disease. Since ARBs and ACE inhibitors differ in their modes of action, combination therapy could provide greater blockade of the RAS as well as provide other vascular benefits.

The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET^TM) Programme will test, in patients at high risk of cardiovascular disease, the cardio & vascular protective effects of a combination of drugs that has already shown individual promise in studies of target organ damage and inflammatory markers.

Faculty

Symposium Chairmen

• Toshiro Fujita - Department of Nephrology and Endocrinology The University of Tokyo, Tokyo, Japan
• Eberhard Ritz - Department of Nephrology Ruprecht-Karls University Heidelberg, Heidelberg, Germany
• Giuseppe Mancia - Department of Clinical Medicine University of Milan-Bicocca San Gerardo Hospital, Monza-Milan, Italy

Session Chairmen

• Eberhard Ritz - Department of Nephrology Ruprecht-Karls University Heidelberg, Heidelberg, Germany
• Giuseppe Mancia - Department of Clinical Medicine University of Milan-Bicocca San Gerardo Hospital, Monza-Milan, Italy
• Björn Dahlöf - Department of Medicine Sahlgrenska University Hospital, Gothenburg, Sweden
• Peter Sleight - Cardiovascular Medicine John Radcliffe Hospital, Oxford, UK

Speakers

• Giuseppe Mancia - Department of Clinical Medicine University of Milan-Bicocca San Gerardo Hospital, Monza-Milan, Italy
• Arya M Sharma - Department of Medicine McMaster University, Hamilton, Canada
• Bryan Williams - Department of Cardiovascular Sciences University of Leicester School of Medicine, Leicester, UK
• Ellen Burgess - Division of Renal Medicine/Endocrinology and Metabolism University of Calgary, Calgary, Canada
• Gordon McInnes - Division of Cardiovascular and Medical Sciences Western Infirmary, Glasgow, UK
• Björn Dahlöf - Department of Medicine Sahlgrenska University Hospital, Gothenburg, Sweden
• Faiez Zannad - Hypertension and Heart Failure Unit Inserm Clinical Investigation Centre, Nancy, France
• Luis Miguel Ruilope - Hypertension Unit Hospital 12 de Octubre, Madrid, Spain
• Michael Böhm - Department of Internal Medicine, Cardiology and Angiology University of the Saarland Homburg/Saar, Germany
• Peter Sleight - Cardiovascular Medicine John Radcliffe Hospital, Oxford, UK
• Thomas Unger - Institute of Pharmacology and Toxicology Charite - University Medicine, Berlin, Germany

Agenda - Friday, 4 May 2007

Hypertensive patients at risk - treat to prevent

• Welcome and opening remarks - Eberhard Ritz, Germany
• The broadening landscape for hypertension management - Giuseppe Mancia, Italy
• Achieving blood pressure control in clinical practice - Bryan Williams, UK
• 24-hour powerful blood pressure lowering: is there a clinical need? - Gordon McInnes, UK
• Does it matter how blood pressure is lowered in patients with metabolic risk factors? - Arya M Sharma, Canada
• Slowing the progression of kidney disease in patients with diabetes - Ellen Burgess, Canada
• Preventing stroke in hypertensive patients at risk - Björn Dahlöf, Sweden
• Questions from the audience
• Panel discussion
• Session close - Björn Dahlöf, Sweden
   

Agenda - Saturday, 5 May 2007

Hypertensive patients at risk - treat to protect

• Cardiovascular high-risk patients - treat to protect Welcome and opening remarks - Peter Sleight, UK
• Treat to protect! But whom? - Faiez Zannad, France
• Treat to protect: current treatment approaches and remaining needs - Michael Böhm, Germany
• Targeting cardiovascular protection: the concept of dual RAS blockade - Thomas Unger, Germany
• Renovascular protection by RAS blockade: are we doing enough? - Luis Miguel Ruilope, Spain
• No HOPE without proof: do ARBs meet the standard for cardiovascular protection? - Peter Sleight, UK
• ONTARGET: a new dawn in cardio & vascular protection - Giuseppe Mancia, Italy
• Panel discussion
• Closing remarks - Giuseppe Mancia, Italy

To start the webcast, please click on the link below. You will then be able to read an overview, the agenda or the presentation abstracts for the symposium, as well as view the presentations. The agenda and programme overview for the symposium are also presented below.

Start Webcast